Identifying therapeutic targets for schizophrenia

There is a continual need to develop new therapies for neuropsychiatric disorders such as Schizophrenia, and identifying the underlying molecular processes remains challenging. Chadha et al. recently discovered a potential role for mTOR kinase activity disruption in Schizophrenia and further uncover...

Descripción completa

Detalles Bibliográficos
Autor principal: Montague-Cardoso, Karli
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Research Highlight
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8192517/
https://www.ncbi.nlm.nih.gov/pubmed/34112930
http://dx.doi.org/10.1038/s42003-021-02270-3
_version_ 1783706063161262080
author Montague-Cardoso, Karli
author_facet Montague-Cardoso, Karli
author_sort Montague-Cardoso, Karli
collection PubMed
description There is a continual need to develop new therapies for neuropsychiatric disorders such as Schizophrenia, and identifying the underlying molecular processes remains challenging. Chadha et al. recently discovered a potential role for mTOR kinase activity disruption in Schizophrenia and further uncover the precise pathomechanism. Their study sheds further light on the role of mTOR in Schizophrenia and could inform the development of future therapeutic strategies for the condition.
format Online
Article
Text
id pubmed-8192517
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-81925172021-06-28 Identifying therapeutic targets for schizophrenia Montague-Cardoso, Karli Commun Biol Research Highlight There is a continual need to develop new therapies for neuropsychiatric disorders such as Schizophrenia, and identifying the underlying molecular processes remains challenging. Chadha et al. recently discovered a potential role for mTOR kinase activity disruption in Schizophrenia and further uncover the precise pathomechanism. Their study sheds further light on the role of mTOR in Schizophrenia and could inform the development of future therapeutic strategies for the condition. Nature Publishing Group UK 2021-06-10 /pmc/articles/PMC8192517/ /pubmed/34112930 http://dx.doi.org/10.1038/s42003-021-02270-3 Text en © Springer Nature Limited 2021 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Research Highlight
Montague-Cardoso, Karli
Identifying therapeutic targets for schizophrenia
title Identifying therapeutic targets for schizophrenia
title_full Identifying therapeutic targets for schizophrenia
title_fullStr Identifying therapeutic targets for schizophrenia
title_full_unstemmed Identifying therapeutic targets for schizophrenia
title_short Identifying therapeutic targets for schizophrenia
title_sort identifying therapeutic targets for schizophrenia
topic Research Highlight
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8192517/
https://www.ncbi.nlm.nih.gov/pubmed/34112930
http://dx.doi.org/10.1038/s42003-021-02270-3
work_keys_str_mv AT montaguecardosokarli identifyingtherapeutictargetsforschizophrenia

Ejemplares similares